Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glabellar Lines Clear all
Completed Phase 3 Interventional Results available

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

NCT03732833
View directory record Official record
Conditions
Lateral Canthal Lines, Glabellar Lines
Interventions
MT10109L, Placebo
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

AI-09 In Subjects With Glabellar Lines, GL-101

NCT05565950
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AI-09, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
20 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Boca Raton, Florida • Miami, Florida • New Brighton, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 7, 2026, 1:31 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

NCT05305768
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Encino, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

NCT05146999
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
QM1114-DP, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
9
States / cities
Homewood, Alabama • Manhattan Beach, California • Vista, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines

NCT05248880
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Newport Beach, California • Redondo Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides

NCT02261493
View directory record Official record
Conditions
Facial Rhytides, Glabellar Rhytides
Interventions
OnabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

NCT04157686
View directory record Official record
Conditions
Glabellar Lines, Lateral Canthal Lines
Interventions
MT10109L Dose 1, MT10109L Dose 2, MT10109L Dose 1 + Dose 2
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
19 Years and older
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • Newport Beach, California • Solana Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

NCT00770029
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Meatrie, Louisiana • Chestnut Hill, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Glabellar Lines

NCT04249583
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
13
States / cities
Manhattan Beach, California • Vista, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

NCT05129319
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
prabotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Subject Satisfaction With AbobutulinumtoxinA Treatment

NCT03687736
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines

NCT00856414
View directory record Official record
Conditions
Skin Aging
Interventions
botulinum toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 55 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
West Palm Beach, Florida • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional Results available

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

NCT04096326
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Fremont, California • Santa Monica, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 7, 2026, 1:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device

NCT01801826
View directory record Official record
Conditions
Frown Lines, Glabellar Frown Lines
Interventions
Treatment with CryoTouch IV
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
30 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Beverly Hills, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 7, 2026, 1:31 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

NCT07435428
View directory record Official record
Conditions
Moderate to Severe Glabellar Lines
Interventions
Corabotase, Placebo
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
41
States / cities
Los Angeles, California • Newport Beach, California • Pasadena, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

NCT05320393
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
Drug
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional Results available

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

NCT05013424
View directory record Official record
Conditions
Glabellar Lines
Interventions
Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Glendale, Arizona • Coral Gables, Florida • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

NCT03004248
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines

NCT01447342
View directory record Official record
Conditions
Facial Wrinkles, Skin Aging
Interventions
Cryo-Touch II
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
30 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Beverly Hills, California • Redwood City, California • Roseville, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677298
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
784 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Encino, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006

NCT02428608
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
DWP-450 (Botulinum purified neurotoxin, Type A)
Biological
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 2 Interventional

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

NCT06246552
View directory record Official record
Conditions
Glabellar Lines
Interventions
JTM201, Placebo
Biological
Lead sponsor
Jetema USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014622
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 7, 2026, 1:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction

NCT06161246
View directory record Official record
Conditions
Injection Site Discomfort
Interventions
Vibrating Beauty Bar
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 7, 2026, 1:31 PM EDT